These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 27291902)

  • 1. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.
    Li P; Snyder GL; Vanover KE
    Curr Top Med Chem; 2016; 16(29):3385-3403. PubMed ID: 27291902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current use of atypical antipsychotics.
    Müller-Spahn F
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The search for novel antipsychotics: pharmacological and molecular targets.
    Sanger DJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors.
    Li X; Ma S
    Curr Drug Targets; 2013 Jul; 14(8):899-918. PubMed ID: 23701299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.
    Kim DH; Maneen MJ; Stahl SM
    Neurotherapeutics; 2009 Jan; 6(1):78-85. PubMed ID: 19110200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Concepts and Treatments of Schizophrenia.
    Stępnicki P; Kondej M; Kaczor AA
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30127324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
    Widschwendter CG; Fleischhacker WW
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.